Drugs / [18F]P16-129
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03902548 | Feb 2018 → Nov 2019 | Alzheimer disease | Five Eleven Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]P16-129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03902548 ↗ |
| Known as | [18F]D3FSP | “A new β-amyloid (Aβ) targeting radiotracer, [18F]D3FSP ([18F]P16-129), for diagnosis of Alzheimer's disease (AD) is reported.” PMID 40544409 ↗ Jun 2025 |
| Modality | Diagnostic / imaging agent | “A new β-amyloid (Aβ) targeting radiotracer, [18F]D3FSP ([18F]P16-129), for diagnosis of Alzheimer's disease (AD) is reported.” PMID 40544409 ↗ Jun 2025 |
| Route | Other | “Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning” NCT03902548 ↗ |